Sonidegib (diphosphate)

• Description :

  Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively[1].

• Product Name Alternative :

  Erismodegib (diphosphate) ; LDE225 (diphosphate) ; NVP-LDE225 (diphosphate)

• UNSPSC :

  12352005

• Hazard Statement :

  H360

• Target :

  Smo

• Type :

  Reference compound

• Related Pathways :

  Stem Cell/Wnt

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/LDE225-Diphosphate.html

• Purity :

  99.97

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : 0.25 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=C(C)C(C(C=C2)=CC=C2OC(F)(F)F)=CC=C1)NC3=CC=C(N=C3)N4C[C@@H](C)O[C@@H](C)C4.O=P(O)(O)O.O=P(O)(O)O

• Molecular Formula :

  C26H32F3N3O11P2

• Molecular Weight :

  681.49

• Precautions :

  H360

• References & Citations :

  [1]Pan S, et al. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010 Mar 16;1 (3) :130-4.|[2]Irvine DA, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016 May 9;6:25476.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  J Genet Genomics. 2018 May 20;45 (5) :237-246.|Nat Med. 2018 Nov;24 (11) :1752-1761. |Patent. US20180263995A1.|bioRxiv. 2023 Nov 6:2023.11.03.565570.|bioRxiv. 2024 Jul 25.|bioRxiv. 2024 Nov 4:2024.10.08.617155.|bioRxiv. 2025 Oct 11.|Cell Physiol Biochem. 2018;47 (4) :1352-1364.|J Pathol. 2025 Nov 6.|SSRN. 2025 Jul 25.|Tissue Cell. 2024 Nov 28:92:102643.

• CAS Number :

  [1218778-77-8]